Key insights
- iBio appointed Elizabeth Stoner to its board, signaling a focus on clinical development. The company is preparing for its first human clinical trial with IBIO-600, targeting pulmonary hypertension. iBio's strong cash position and undervalued stock, according to InvestingPro, suggest potential upside as it advances its pipeline.
SAN DIEGO - iBio, Inc. (NASDAQ:IBIO) announced today the appointment of Elizabeth Stoner, M.D., M.S. to its board of directors as an independent member and member of the compensation committee, according to a press release statement.
The appointment follows the departure of Eef Schimmelpennink, who stepped down from the board.
Dr. Stoner brings more than 35 years of experience in research and development leadership. She currently serves as an entrepreneur partner at MPM BioImpact, a biotechnology investment firm, where she works with portfolio companies on clinical strategy and development.
Her previous roles include interim chief executive officer of Semma Therapeutics and founder, chief medical officer, and chief development officer of Rhythm Pharmaceuticals. Dr. Stoner also served as senior vice president of global clinical development operations at Merck Research Laboratories, where she led clinical development activities across more than 40 countries.
Dr. Stoner currently serves on the boards of Antiva Biosciences and LIB Therapeutics.
iBio is a biotechnology company developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, with a market capitalization of $59 million. The company stated it is preparing for its first human clinical trial. According to InvestingPro analysis, the stock appears undervalued at current levels, trading below its Fair Value.
The company’s pipeline includes IBIO-610 and IBIO-600, which are in development for potential treatment of obesity and pulmonary hypertension associated with heart failure with preserved ejection fraction. An InvestingPro tip notes that iBio holds more cash than debt on its balance sheet, a positive indicator as it prepares for clinical trials.
In other recent news, iBio Inc. received approval to commence a Phase 1 clinical trial for IBIO-600. The trial, set to begin dosing participants in the second quarter of 2026, aims to evaluate the safety and effectiveness of the compound in overweight and obese adults. Meanwhile, Leerink Partners reiterated an Outperform rating with a $5.00 price target on iBio stock, citing competitive data from Wave Life Sciences. This data showed significant fat reduction and lean mass stabilization in a competing compound. Additionally, Jones Trading maintained a Buy rating and a $7.00 price target for iBio, following the company’s announcement of expanding its pipeline into pulmonary hypertension treatment. The firm also commented positively on preclinical data for IBIO-610, which demonstrated a 6.7% reduction in visceral fat in a primate study. This preclinical study also indicated a 5.2% reduction in total fat mass, with lean mass maintenance despite a high-calorie diet. These developments highlight iBio’s ongoing efforts in clinical trials and product pipeline expansion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.